Biogen Idec has posted fourth-quarter results which show that sales of its oral multiple sclerosis pill Tecfidera have comfortably passed analyst forecasts, pushing net profits up 46%.

Earnings came in at $882.6 million, while revenues increased 34% to $2.64 billion. The biggest earner was Tecfidera (dimethyl fumarate), bringing in $916.0 million, up from around $397.6 million a year earlier. Some $743 million of that came from the USA and the figures exceeded analyst expectations.

As for Biogen’s other MS drugs, Avonex (interferon beta-1a) slipped 2% at $736.0 million,  while Tysabri (natalizumab) contributed $483.9 million, up 13%. The rheumatoid arthritis and cancer drug Rituxan (rituximab) and the recently-approved chronic lymphocytic leukaemia treatment Gazyva (obinutuzumab) partnered with Roche brought in $305 million.

Chief executive George Scangos said 2014 “was a remarkable year for our company”, noting that the growth of Tecfidera, “the improved performance of Tysabri and our entry into the treatment of haemophilia demonstrated our strength as a commercial organisation”.

The results were published hours after Biogen announced a collaboration with Italy’s Fondazione Telethon and Ospedale San Raffaele to jointly develop gene therapies for both haemophilia A and B.